0000947871-09-000808.txt : 20091222 0000947871-09-000808.hdr.sgml : 20091222 20091222094658 ACCESSION NUMBER: 0000947871-09-000808 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20091222 DATE AS OF CHANGE: 20091222 GROUP MEMBERS: ALKALOIDA CHEMICAL COMPANY EXCLUSIVE GROUP LTD GROUP MEMBERS: SUN PHARMA GLOBAL INC. FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SUN PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0001197089 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: SPARC AKOTA ROAD CITY: VADODARA STATE: K7 ZIP: 390020 BUSINESS PHONE: 01191228212128 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TARO PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000906338 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49231 FILM NUMBER: 091253757 BUSINESS ADDRESS: STREET 1: 14 HAKTOR ST CITY: HAIFA BAY STATE: L3 ZIP: 26110 BUSINESS PHONE: 9143459001 MAIL ADDRESS: STREET 1: THREE SKYLINE DR CITY: HAWTHORNE STATE: NY ZIP: 10532 FORMER COMPANY: FORMER CONFORMED NAME: TARO VIT INDUSTRIES LTD /ISRAEL/ DATE OF NAME CHANGE: 19930601 SC 13D/A 1 ss80697_sc13da.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

(Amendment No. 14)

Under the Securities Exchange Act of 1934

TARO PHARMACEUTICAL INDUSTRIES LTD.

(Name of Issuer)

ORDINARY SHARES, PAR VALUE NIS 0.0001 PER SHARE

(Title of Class of Securities)

M8737E108

(CUSIP Number)

Mr. Sudhir V. Valia, Acme Plaza, Andheri Kurla Road, Andheri (East), Mumbai 400 059, India

(Name, Address and Telephone Number of Person Authorized

to Receive Notices and Communications)

December 22, 2009

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D/A

CUSIP No. M8737E108

Page 2 of 7 Pages


1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SUN PHARMACEUTICAL INDUSTRIES LTD.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) x
3	SEC USE ONLY
4	SOURCE OF FUNDS (See Instructions) PF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			o
6	CITIZENSHIP OR PLACE OF ORGANIZATION The Republic of India
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 18,143,927*
		8	SHARED VOTING POWER 0
		9	SOLE DISPOSITIVE POWER 18,143,927
		10	SHARED DISPOSITIVE POWER 0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 18,143,927
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 41.95%**
14	TYPE OF REPORTING PERSON (See Instructions) CO

* Includes 3,770,833 Ordinary Shares acquired by Alkaloida Chemical Company Exclusive Group Ltd. (“Alkaloida”), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. (“Sun”), on May 21, 2007 and 3,016,667 Ordinary Shares acquired by Alkaloida on May 30, 2007, in each case pursuant to the share purchase agreement dated May 18, 2007 (“Purchase Agreement”), between Alkaloida and the Issuer, which entitled Alkaloida to acquire a total of 7,500,000 Ordinary Shares; 58,000 Ordinary Shares acquired by Sun Pharma Global, Inc. (“Sun Pharma”), a direct wholly-owned subsidiary of Sun, on July 11, 2007 and 500 Ordinary Shares acquired by Sun Pharma on July 23, 2007, in each case in open market transactions; 3,000,000 Ordinary Shares acquired by Alkaloida on August 2, 2007, pursuant to Sun’s rights under the warrant, dated May 18, 2007, issued by the Issuer to Sun (the “Original Warrant”); 3,712,557 Ordinary Shares acquired by Alkaloida on February 19, 2008, from Brandes Investment Partners, L.P., for and on behalf of certain of its investment advisory clients (“Brandes”); and 797,870 Ordinary Shares acquired by Alkaloida on June 23, 2008, from Harel Insurance Company Limited (“Harel”). This amount also includes 3,787,500 Ordinary Shares which Alkaloida has the right to acquire pursuant to a warrant issued to Sun by the Issuer on August 2, 2007 (“Warrant No. 2”). On December 1, 2009, Sun exercised Warrant No. 2 and nominated Alkaloida to purchase the underlying shares at the exercise price stated in Warrant No. 2 of $6.00 per share. By letter dated December 1, 2009, the Issuer refused to issue such shares, citing an opinion of counsel to the Issuer to the effect that exercise of Warrant No. 2 would violate the temporary injunction issued by the Supreme Court of Israel in connection with ongoing litigation between Sun, Alkaloida, the Issuer and other related parties (the “STO Litigation”) and would require the approval of the Israel Land Administration and possibly other governmental authorities.

** Based on 39,460,257 Ordinary Shares outstanding as of June 30, 2008 as reported by the Issuer in its Solicitation/Recommendation Statement filed on Schedule 14D-9 on July 10, 2008; and an additional 3,787,500 Ordinary Shares that should have been issued to Alkaloida on December 1, 2009 upon exercise of Warrant No. 2.

SCHEDULE 13D/A

CUSIP No. M8737E108

Page 3 of 7 Pages


1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SUN PHARMA GLOBAL INC.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) x
3	SEC USE ONLY
4	SOURCE OF FUNDS (See Instructions) PF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			o
6	CITIZENSHIP OR PLACE OF ORGANIZATION The British Virgin Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 18,143,927*
		8	SHARED VOTING POWER 0
		9	SOLE DISPOSITIVE POWER 18,143,927
		10	SHARED DISPOSITIVE POWER 0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 18,143,927
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 41.95%**
14	TYPE OF REPORTING PERSON (See Instructions) CO

* Includes 3,770,833 Ordinary Shares acquired by Alkaloida on May 21, 2007 and 3,016,667 Ordinary Shares acquired by Alkaloida on May 30, 2007, in each case pursuant to the Purchase Agreement; 58,000 Ordinary Shares acquired by Sun Pharma on July 11, 2007 and 500 Ordinary Shares acquired by Sun Pharma on July 23, 2007, in each case in open market transactions; 3,000,000 Ordinary Shares acquired by Alkaloida on August 2, 2007, pursuant to Sun’s rights under the Original Warrant; 3,712,557 Ordinary Shares acquired by Alkaloida on February 19, 2008, from Brandes; and 797,870 Ordinary Shares acquired by Alkaloida on June 23, 2008, from Harel. This amount also includes 3,787,500 Ordinary Shares which Alkaloida has the right to acquire pursuant to Warrant No. 2. On December 1, 2009, Sun exercised Warrant No. 2 and nominated Alkaloida to purchase the underlying shares at the exercise price stated in Warrant No. 2 of $6.00 per share. By letter dated December 1, 2009, the Issuer refused to issue such shares, citing an opinion of counsel to the Issuer to the effect that exercise of Warrant No. 2 would violate the temporary injunction issued by the Supreme Court of Israel in connection with the STO Litigation and would require the approval of the Israel Land Administration and possibly other governmental authorities.

SCHEDULE 13D/A

CUSIP No. M8737E108

Page 4 of 7 Pages


1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) ALKALOIDA CHEMICAL COMPANY EXCLUSIVE GROUP LTD
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) x
3	SEC USE ONLY
4	SOURCE OF FUNDS (See Instructions) PF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)			o
6	CITIZENSHIP OR PLACE OF ORGANIZATION The Republic of Hungary
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER 18,085,427*
		8	SHARED VOTING POWER 0
		9	SOLE DISPOSITIVE POWER 18,085,427
		10	SHARED DISPOSITIVE POWER 0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 18,085,427
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 41.82%**
14	TYPE OF REPORTING PERSON (See Instructions) CO

* Includes 3,770,833 Ordinary Shares acquired by Alkaloida on May 21, 2007 and 3,016,667 Ordinary Shares acquired by Alkaloida on May 30, 2007, in each case pursuant to the Purchase Agreement; 3,000,000 Ordinary Shares acquired by Alkaloida on August 2, 2007, pursuant to Sun’s rights under the Original Warrant; 3,712,557 Ordinary Shares acquired by Alkaloida on February 19, 2008, from Brandes; and 797,870 Ordinary Shares acquired by Alkaloida on June 23, 2008, from Harel. This amount also includes 3,787,500 Ordinary Shares which Alkaloida has the right to acquire pursuant to Warrant No. 2. On December 1, 2009, Sun exercised Warrant No. 2 and nominated Alkaloida to purchase the underlying shares at the exercise price stated in Warrant No. 2 of $6.00 per share. By letter dated December 1, 2009, the Issuer refused to issue such shares, citing an opinion of counsel to the Issuer to the effect that exercise of Warrant No. 2 would violate the temporary injunction issued by the Supreme Court of Israel in connection with the STO Litigation and would require the approval of the Israel Land Administration and possibly other governmental authorities.

This Amendment No. 14 amends and supplements the Statement on Schedule 13D originally filed by the Reporting Persons with the Securities and Exchange Commission on July 3, 2007 (the “Original Schedule 13D”); the Amendment No. 1 to the Original Schedule 13D, filed on July 25, 2007 (the “Amendment No. 1”); the Amendment No. 2 to the Original Schedule 13D, filed on August 2, 2007 (the “Amendment No. 2”); the Amendment No. 3 to the Original Schedule 13D, filed on February 19, 2008 (the “Amendment No. 3”); the Amendment No. 4 to the Original Schedule 13D, filed on May 29, 2008 (the “Amendment No. 4”); the Amendment No. 5 to the Original Schedule 13D, filed on June 5, 2008 (the “Amendment No. 5”); the Amendment No. 6 to the Original Schedule 13D, filed on June 24, 2008 (the “Amendment No. 6”); the Amendment No. 7 to the Original Schedule 13D, filed on June 25, 2008 (the “Amendment No. 7”); the Amendment No. 8 to the Original Schedule 13D, filed on December 2, 2009 (the “Amendment No. 8”); the Amendment No. 9 to the Original Schedule 13D, filed on December 11, 2009 (the Amendment No. 9”); the Amendment No. 10 to the Original Schedule 13D, filed on December 14, 2009 (the “Amendment No. 10”); the Amendment No. 11 to the Original Schedule 13D, filed on December 15, 2009 (the “Amendment No. 11”); the Amendment No. 12 to the Original Schedule 13D, filed on December 17, 2009 (the “Amendment No. 12”); and the Amendment No. 13 to the Original Schedule 13D, filed on December 21, 2009 (the “Amendment No. 13”, together with the Original Schedule 13D, the Amendment No. 1, the Amendment No. 2, the Amendment No. 3, the Amendment No. 4, the Amendment No. 5, the Amendment No. 6, the Amendment No. 7, the Amendment No. 8, the Amendment No. 9, the Amendment No. 10, the Amendment No. 11 and the Amendment No. 12, the “Schedule 13D”), with respect to the Ordinary Shares, par value NIS ..0001 per share (the “Ordinary Shares”), of Taro Pharmaceutical Industries Ltd., an Israeli corporation (the “Issuer”), whose principal executive offices are located at Italy House, Euro Park, Yakum 60972, Israel. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

Item 4. Purpose of Transaction.

The response set forth in Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following paragraph after the last paragraph of Item 4:

“On December 22, 2009, Sun issued a press release announcing the report of Glass, Lewis & Co. LLC, an independent proxy advisory firm, recommending that shareholders of the Issuer vote against all of the proposals made by the Issuer’s board of directors, including all of its nominees for election or re-election as directors, in the Annual General Meeting of the Issuer’s shareholders scheduled for December 31, 2009. Sun’s press release is filed hereto as Exhibit 99.30.”

Item 7. Materials to be Filed as Exhibits.

Exhibit No.

Description

99.30

Text of press release issued by Sun on December 22, 2009.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:

December 22, 2009	SUN PHARMACEUTICAL INDUSTRIES LTD.

	/s/ Sudhir V. Valia
	Signature

	Mr. Sudhir V. Valia
	Director
	Name/Title


	SUN PHARMA GLOBAL, INC.

	/s/ Harin Mehta
	Signature

	Mr. Harin Mehta
	Director
	Name/Title


	ALKALOIDA CHEMICAL COMPANY EXCLUSIVE GROUP LIMITED.

	/s/ Harin Mehta
	Signature

	Mr. Harin Mehta
	Director
	Name/Title

EXHIBIT INDEX

Exhibit No.

Description

99.30

Text of press release issued by Sun on December 22, 2009.

EX-99.30 2 ss80697_ex9930.htm

17/B, Mahal Industrial Estate,

Mahakali Caves Road,

Andheri (East), Mumbai 400 093 India

Tel.: (91-22) 6645 5645

Fax.: (91-22) 6645 5685

For Immediate Release

Glass Lewis Advises Taro Shareholders to Hold Taro’s Board Accountable for its Failures

Mumbai, India: December 22, 2009: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that Glass, Lewis & Co. LLC, a leading independent proxy advisory firm, recommended that shareholders of Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) vote against all of the proposals made by Taro’s board of directors, including all of its nominees for election or re-election as directors, in the upcoming Annual General Meeting of Taro’s shareholders scheduled for December 31, 2009.

In its report, dated December 21, 2009, Glass Lewis cited the Taro board’s failure to file its annual reports for fiscal years 2006, 2007 and 2008 and its twice-restated financial statements for fiscal years 2004 and 2005 as proof that the board is “unable to fulfill its responsibilities to shareholders.” Referring to the eight incumbent directors up for re-election, Glass Lewis advised that Taro’s “shareholders should hold them accountable” for their “serious disservice to shareholders” by voting against them at the Annual Meeting, concluding that “the presence of new directors on the board might provide fresh perspective and a much needed transparency in the operation of the Company.”

Glass Lewis identified additional serious corporate governance and disclosure problems by the Taro Board, including lack of disclosure regarding members of board committees and the number of times such committees met. Glass Lewis was “especially concerned about the lack of disclosure regarding the audit committee,” noting that without such disclosures, it is not possible to ascertain such fundamental issues as the existence of proper oversight of the company’s accounting, financial reporting and internal and external audits.

As reasons for its recommendations against the board’s proposals for indemnification, Glass Lewis reiterated the board’s lack of transparency and its inability to provide shareholders with reliable audited financial information. Glass Lewis contrasted the “seriousness of the accounting issues” with the “limited information provided to shareholders” regarding those issues at the Company’s last shareholders meeting.

The Glass Lewis report was released only three days after similar positions were expressed in a report by PROXY Governance, Inc., another leading independent proxy advisory firm. Neither advisory firm supports the Taro board’s director nominees or its indemnification proposals.

Sun encourages fellow Taro shareholders to follow the professional advice of Glass Lewis and PROXY Governance and vote against the re-election of the incumbent directors and their nominees for external directors and against the board’s indemnification proposals by signing, dating and returning their proxy cards immediately.

For questions or assistance in voting or changing their votes, Taro shareholders can contact Sun’s proxy solicitors, MacKenzie Partners, Inc., within the U.S. and Canada at 1-800-322-2885 (toll-free) or 1-212-929-5500 (call collect), within Israel at +1-809-494-159 (toll-free) or via email at proxy@mackenziepartners.com.

About Glass Lewis

Glass, Lewis & Co. LLC is a leading independent governance analysis and proxy voting firm, serving institutional investors that collectively manage more than $17 trillion in assets. With research focused on the long-term financial impact of investment and proxy decisions, Glass Lewis empowers institutional investors to make decisions by uncovering and assessing business, legal, governance and accounting risk at more than 18,000 companies in over 80 countries. More information about Glass Lewis is available at www.glasslewis.com.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota		Mira Desai
Tel	+91 22 6645 5645, Xtn 605	Tel	+91 22 6645 5645, Xtn 606
Tel Direct	+91 22 66455605	Tel Direct	+91 22 66455606
Mobile	+91 98670 10529	Mobile	+91 98219 23797
E mail	uday.baldota@sunpharma.com	E mail	mira.desai@sunpharma.com

Brunswick Group for Sun Pharma		MacKenzie Partners
Erin Becker/Nicki Kahner		Robert Marese
+1 212 333 3810		+1 212 929 5500

Arad Communications for Sun Pharma		Greenhill
Irit Radia		Ashish Contractor
+972-54-6699311		+1 212 389 1537

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`(H`:@,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/W\H`*`"@`H`*`"@!I8+QT]NG7]*`%!';C\OZ'ZT`+0`4`% M`!0`4`%`!0`4`%`!0!0U/4;'1]/O=3U*[AL-/T^UFO+R]N)%A@M;:W0R33RN MQ`1$168GV]3@S.<*4)3FU"G33E)MV44E=MOIH.,6Y*,8N3;LHQW;?16[GR1X MB^,OB[Q-/-%X6>7P?X;64K;ZE);0W7B?6K<,%%W#!>(]MX=LY`*F*I4\9F MLY4(U/AH1;C+EZ-VV?X_>5J5WHJ5:=-1U^RK\J7RUV6I]Y#A'(\/3C"& M74I**^*I3C4EMUTYF_._FS5TW7/%/AV6.30/%&MV;(X9;74]1O\`Q'I#("H: MWGTO5[J3RH6QAGLYK25?X9!71@O$;B;*\33<\:\RPZ;O1Q"NIJVRJTX>TC+K M%IVO;FTO?SL?P3DF*HU'0HK!5K>[4IN4%%]_9RG[-]K./HTSZ*^'WQ7A\2W: M:!XAMHM#\4".62W@AF>?2M=@@C5YKO1[B5$=)5#%I+"8>?$IW`S1CSC^Z<,< M799Q+AG5PLG0Q5-+VV%G=2I2Z\LI*+G'SZ7Z=?R?.>'L?D=2*K1=3#2NHUTH M\D^UU%OD>]EI?7>Q[*#P,5]8GHGLCQ-OD+3`*`"@`H`*`"@`H`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`5JDO=E+$STVVBK+Y:V1L?"/X>Z]\0O$OB'Q+J&I76C>`]/ MN'\.:*=+E^S:QXBELPJ>(9K35%3S=*TLZD9;-[FS=;B<6#11311&3S_U_P`. M^%Z.79-#,*M.V,S*TVI=();>C?3YGY=QKG\\RS:6%P[MA<#>G=-I<]]7ZK:Y M]DZ=X&\'Z1;&UT_PSH5M$P'FXTRT:66,4K;)*R/BFW=ZO7?_@GDWCSX)V.P^*/ACL\#>--/W7$<6@A-,\/^)HP M"9]*\1:#&!IE\9UXBO9K4SP2[7$H0N&X<=@5B:-2-/EIUVO<=E;FW2EV3V?D MSHPV)EA:L*EWR4WJDWL^R[]CA/`_CM?$L4>GZW:QZ)XC59$:V??;V]]-:2M# MJ-O:P2,S6>JVT\@3J%&Z\AC?S=-N"P&=.U*`/9W"$X*7.\8=%(]#+<3+`5U*[4+ MVDKNVK6K7?S.3-<(L3A:B@E[2*YH=/>5W;YW9[QX8URS\2Z#H^OV&X6FK:;: M:A"K\21"ZA21H)4_@GB=FBD4X*NC`\BOOHR4HQG#X)KF7S/A5LI?#*6Z[-:, MWZH84`%`!0`4`(>AI/9@>$N-NL>*&/R,?$5R6!X(":=IL4>,8)'DI'@\'``] M*^+SO3,)=$H4OT/L,C3^HQ4=^>=O6[L?.GBJ&;1_&NM6Y0BWU_3X]-X].FXRQ6\8C[AQ^0\;Y=/ZQE..6F&C-8/$]/?A+GIGWW M#6,<8YC@G;;ZUA_6HN2?WO6Q]=_"*VM+7X8^`HK%$2W;PKHEPJQ@*OG7=A#= MW38'\;74TS,3R69B>37]%81*GA<+&FK1]E3^[E1^*57)U:KG\7M)^7VF>CUT MD#6'RX_S^5&BMY;>H.]K1/@GXB:3:_\`"Q?B)I^EO'!.NJZ#KUI)&QSI7B"; M0M-NA?H(MGE2B[@AG9=P+">3=D2D5^%\=8EY1Q?@,?A)HP7"*2!P@]<5]15G3DHU:-3GI5(1G!>52TF_OT/)IJ: MA*G55JE*7LY>L)J)WGP=.WPC/`H"Q6GBKQM:VR`!0EO'XNUDH@`X`!9A7Z'@ MG_L>%MI^[1\%B%;%8NVWMZOXR/5:Z3(*`"@`H`*`"@#PW72--\9ZCIL^U$U^ MVA\0:5R(_/EL[:VTC6K.%<_/);K;:9=G`W$:FYZ1$CY3B"C[*I3Q"NE.-I-+ M;S_$^ER'$VFCW+NCG8@JZJR_%YEA*.+H2P>(YI4I+F4XZ3@]U)>:>I]32J MRP\X5J"7-3=VNCMNOF8WP<^)5OX0U"V^#_CI!X:U&.61O`EYJ$H32_$%C=3S M3MHFF:LRK;W5]9R2.MO;DQW$EMY*M")87W?=\.XFN\)3PF*<)5,-%*%6.D:U M-:*;CO&JM$]K[VW/A\[H0P^.G.E'V-*M[SCLH3>KIQ?\KW/K<$#N![=,=>U? M26[;'D_E_F<5X^\<:-X`\.WVNZN7D6WBD^QZ?;;6OM3NUADFCL[2,D#&PTJ"RM@[JA;RBVQ= MVU?YBXQSK^UL^Q.(@DJ5#FHT+;4O*,CP]&K_&JN5:I?2S MG9V^2L>V^"=171_`LVHW*XAL=6\4/!#&23/N\1ZF+>TA122\]S>R")409+R+ MQC)K]-R2A4Q&4Y+":=YX6DM%M&\O^`?$9I.EA\9FE2%DHXBKI_>Y5?\`S/H+ MX=Z!<>&?".CZ5>LIU(17&H:LR?<.KZQ>3ZMJ@0Y.Z-;V]F1">2L:YK]0I4E1 MI4::VI04?R/SCFYO?^%R>&+^Y2-=13+H9;,'[7;>:/.CVXDD^&S3`/`3C4D_P!U.5HV[M[>OXGV M>`S6AB81HS_=55O;LEOZ>9?UC0-'\1Z?<:-XAT;3]8TR=1YMAJ-K%=6Y.3B0 MQNNZ*52Z].QDQ:?_PB M6FF"S\<^*O#VA6L0CCM[KQ!97=E8P$D*EO?>++"_NK>!`I"H+W"*H50%`4>Q M'/<11@^9-QBM%>VO1W>EKV;\KGE3R'`MH)_DE^%D>/:[?:=KM[)%I MBZC?V;[8]6\4Z[?:A?:KKL4$C2II.G/J>7L]!%PD)JT'1I4'S0]HO?K M.VFO17U(-0U&VTC3I]1N9"EKIMJ]PYV,TDGEJ66**)`6DF=P$2-06=G"JI)` M/YQ@Z-?&5L-A,-!U*]2244DWJWJ].BOJ^Q^@8JM2P5&MB*[4817O)M)026RO MU?;J>\?!KPIJNM>'?"&L^*M/NM+L]+MO[5TG0M0MFM;NXUN^N+G4)M&6T*-'FUP]&E0BNB4(KG?_`&]-W/YQ MQ^9/&SJS2M[6M4K3]:DGRK_MV*L^Q]+`8X]OI7MI6271'F6L[[#J!A0`4`%` M!0`4`%&WR`\U^)_PZTWXC>'FTNZCM(]2L9?M^@:A=VBWL6GZFD4L0,]LQ7[5 MI]Q!-+;7-N6`EAG;D.B,OFYIEM'-,#7P5:THMZ*47JCJP. M+G@,5#%4Z<9RIZF:G9V5TLF`WD;(KI=X$T",EA<5)VGA:LW3O/K*E)N/ M/?I&"T730OVVA:=;3>>UO-/&.1G,]RYAL[2**6YU"^GP0(++3[9'N+R4D_=AC8^W% MZ_#+X5ZG+J=IXO\`&5H=-2QQ+X=\+R%));:2_I_32J%X'&.G:OT%:-^>I\AMHM!U,`H`*`"@`H`*`,;5_$6@^ M'XXY=;UC3=)25MD!U"\@M#._=($F=6F<=U0,?44!HCF[[XG^`=/L[J]G\5Z( ML5E$LT\*W]N;P(S;08['S!/*2<8"1L3N!`H`ZJ[UG2=-2"34-3T^P2Y)%LUY M>6]HEQA0Y\EIY5$OR$-\I/!!I-:6V#;Y&'?ZKX(UBUEL=1U/POJ=E.%\ZSO; MW2;RUE7`=3)!/(\;KMPP)4C'-3.$9)%J5/YI48N5WZ6777R.^GFF:8>G[&AF&(H4OY(57&/?K=_B;/AK0?A M3X8G:Z\.6OA#3[UHS%+J-O/ILVJ/&R@F.?4II9+J16V@E7E(.T'!(X[L/A:& M$C[/#8>EAH+[-&$::^:23_$Y:M:M7DIXBM.O46TIRE)KOJW;\#M_^$AT``?\ M3O2%'0?\3&S`)Y.`?.ZX!/ZUT>2,]O*QHV]U;748EM+B&XBY`DMY4EC)'4!X MV*Y'&1GO[T6MI:P>A%-J.GVLGE7%]9VTF`PCFN887VDD!MKN#@D$9QU!H#;R M%@O[&X)6VO+66,8/S>5CCUH`^2_P!FOQ-IGC/6?&/BCQ7J-M>^ M/KG4H&LDU!T1].T*6W#16F@6]PY%O:I<"2.3[.JGY(RY)D)9V:Z6(7D?27C[ MX>>&?B'HL^CZ]8Q2.T;BQU)$5=0TNX(/EW%G<8W)ACEHR=D@.'!P,(O\#FO" M_AF3Q%\.5\*_$#1X;_4]%CO_``W-+J-HCK="Q4VVGZSI\SJ<&XTYK.47$+[E MD#+N#QL%%IY)!MY6/@#X$^&]-\0_%70=$U6TAO;&*[UB>ZMYL-#/S$C)7)#=&!!-6]%V[&4?C=NGR/U2M]*TRRL_[.M=/LK;3RCQFQ@M8( M;,I*")4-M'&L>U]QW#;\V3G.:@UV\CP#7?A!X.?XO>#-5@T#2;>QDT;Q'=:A MI45A:QZ;>:CI3:6NGW,MDL8B\Q/[5D=ODPY@B+`LH(`TVV*GQA^#GA?Q._AJ MPT?2-+\/ZQ=76LI;W^F6%K8"62WT'4M1M[:_6VB1)K:2[M8@S.K,@B/$/V<_'LW@+Q3J?P\\2?\2VRU+47M_+N@T']D^)8F2V,1##"6]XJ(A= MMH\Q(#T#O$,USIM@-;M-%O+O3=8:TB.H6D]A; MRWD$:76T2^070H8M^W$K'&:SV^0VM--"7X2?#[P[X*\):`NG:59P:M/HMC+J MFK?9X#J=Y=7<$-S=)-?!/,:W6WNX7MYE##[I, M_BC0(+B2XL[W2HP^KP0!_.B2[TR-_.$L:JPWVRSJQ7/RY51=UZ&6*`D*5AEC"Y^Z.*+ M1Z/7IN'/Y:'Z"?"3XI67Q.\/S7T=LNFZMIKQP:QIHD\V.&26,M!V$<-X+?3_ M`!28&$;1SG%O8ZLXW;F5U\FVD,:Y4I&QSN8T[Z6VL1)-+1?#KVL>B?!WXI?\ M)[\*M>TW4[CS/$GA?PYJ%I?O(\?F:C8_8+R+3]4RF,LTPLS$^:#2 MY7IIH.G+F6G3Y'T?X>*_V%HQ3@?V5IV.HX^QPXZ\]*5K>19L4`%`!0!DZZNJ MG2-2&ARQ0:NME&??&1G`#`,K6 MC72PFE9Z6/%_V2_#FJ6FB>(?$MY$]O8ZV]A9:9O0I]JCTT78N;R,?Q0F:Y\L M'D%HW'5.&VKW7^0HIQMTL>$?`D?\(S\>;?2M7C%A=6>K>*M)E65]I%]/:WL5 MO%C[H\QCA.?FW#;G(IO8RBN6;Z=C].P1C/0?EBH-S@+R47/Q*T*VA5F_L;PK MX@O+]U!*6_\`;%]H=MIL4A'"R3_V=J+JIY(M&.,#-&PK:IK1(RO&OB/3M'\: M?"_3[N9(9M6US6HK<,Z(/^1=O[9,[O[US=PQC&/F<#J<4#V\CT+5M*L=6R/S&U?2O$7[/GQ"U3 M3;%VNM.U'2-0M;*6Z218-9T#5%:%89=DG_'U:W&P$@\2P`_=DYM-62V,9_NV MN16B]#]&O`/B'2O$WA31-5T:X-Q926%M!N,,MNT=Q;0QPW$+13*&1HY5*]P< M94L#FI?EH;+9?\,=E2`*`"@!"=H]/3M0!X&GP(T5?'/B;QJFN:]I5SK=Q;W= MC'X?OFTB73IFA7^TVDG2-_M2W-V&E$;J4`D<%&R30!U]]\-+'68HK7Q/XC\5 M>*-,C>-VT?5;^QM]+N?*96B&HVNAZ98?VD@<;MER\R$X)4[1@`]#M;:UL+:& MSM+>*TMK:-(;>WMXUBA@AB4+''%'&`L<:J``J]!BC;Y`>9^,_@[X%\;7RZMJ M6GSV&NQ^5Y>O:'K!HBA@>2:(%)WC*KL>:-V3'RD4[]!62>FEC1L_!OB" MTMDL_P#A9'B^XLT5HU^T6WA62_,98D*VIOX>,[2!<*)6)?H22>:0]CI-"\.Z M=X<@ECL5G>>ZD$U_J-]#D`DDC(`_ M`];T+23HEA'I_P#:>K:LL)8K>:U=)>7Y!VA4>X2&+S$4#`+*6]68G-`;?(Y7 MQM\-/"_CVZ\/77B*R-RWAS47O[6-61%N5D3:]E>';NDLFE6"9HU9,M``3M9@ M3;RL%EUTML=Y;P06L,=O;0Q6\,"!(H($2**)!T2..(*J+UP%`'M1Z!MHM+$] M`!0`4`<3\1)&A\(ZFRIJ$F9--B>'2)Y;75)X9M6L(9[:PG@N()(KN:*1XT*2 MQG=(/F'6@#S#0[KQ+X>UFP2WT#Q=J6G7L'BF;2?#VJ:Y8SZSINF13^%!'<7U MSKFO[6C^VF]$$+WES-%'>*,*K$(!L9/ASQ7*NO?#:*YUR6`G0++3[_1KFY:1 MM0NO%"ZG.+BY(F>.:ZM+C2--B5V8G-^ZH6$U`&'87%ZVC,FBQ^+M$UBX\+?: M[N]UN]U.2QUN^A\0^'OLU[HJW.I74<@5Y9UD:);<&*^5&C82?(TM>5:"O;R. MFU#Q4]SJGQ$U`ZO/9Z)?>&O"^E:5*MW(L%E)J-W>:;J%]9B,D1W4@+=^,XK6RB\6:M9V?ASPEI(L[S1]1FLY;W6I+K6= M,EUC464JU]#'_8*$6\_[MFN)C*K%AMFU@O;Y&9`;HW?CZ^FB\77>IZ9'K'V/ MQ38:U/:^%$D@\%V4ZF+2XO$&()#=32R1A-/E023QL),C<%MY6"Z7E8Z;Q:+N M_N;^W_M'6;*&U^&=YKD+:7K.I:41JMM.6AGDEL+F)G<`$'>2&''3.#T_JX7Z M$5M!>C48?"T.MZ_#9:A#X<:XO7UO4+C5HH?[)U_5KN.SU.[GDN()+FXL[>-Y M$?<(@RH5(5D=K>0;%7Q/K,_@R]\#V5YXODEAM-=OKF2._P!11+_5],N+JQT6 M#3;YB0VI362Z^]P6(W'^SXGE^<;RU'M[MOD)Z6Y=+?(](\#S74NDWC7<\D\L M?B+Q/"))9'E;R8=>OXX$5V8_NTA"*H!P`H`X&*35@C?T.RI%!0`4`4=1T^#4 MK4VEQO\`)\ZUN"(V,;;[.[@O(<,.@\ZW3([C(XSD`&5<#1FUZQNY+^WCU2TM M[W1[:S-S;*SMJB66IRQ-`1YQN?LVEQS(J,N8Q(VUA@J!^!PW]F_#W2=,/@F? MQ196DVJ7=OG75M;6QL%;8SM#>Z3'$$2%@)(Y$P6)`%HUY` M=%#X:T&(8[^5QX8B71H'-U:L[L;O2;H6U^1#\]R]QI]A^[58R?-(VY=<- M:-LDY+3=&^&6@K8:E;^*=.BL_#MS]C22?Q'I*6,&H-=:U?+%J$JNB&[\S5KT MK%)("!!&0F8V+N_0=K?(CN[3P!J.H(^D_$&TTF_UH7D$\>C>)/#[SZ[8ZI?W M%S-IR0W*W!VF_FN_)N+18[B-YYDCF&XA7TML+;;0D.C^#="U1XI/B&=+TS6V MEB/@RZUOPS#H^I#[$OAR6W@CNK$:DZXM8H6$-[N$UMM)!#*9M;RL%OD;&@>& M-`MGU_2$\5ZAXAOY]*30;N&_U33+K4=$T9([I+>Q6&PM86@"B[D/G7<^ MNX9HYHY499F`13R'^%@:MY&3:Z!X1$VJ:'-XCAU76-:TMX;RWNK_`$>35Y// M>\FN-5BLX(HVBEE-RIRD(A5+.$(@6/YG?1):6$E^!M>&?!L_AJYF>+Q1KVH: M?-)>3C2+]-'^Q0W-_Y90)FRIP,3M\AI);Y=)E:#5M.\3Z=J^CL"0)-0TSP)/O:!X\U/4%MUT[4/#M_)_B&6A"S$-%:B]6`%-;KU&=#97T0T&^M-0N1!J#>*](%["SHUXC26VAWT\@MQ\[N M(%FFVA.0C$`XJVEK;305K>1SMO;+;Z+XHTZ^L?#U[<1?"Z[;2O$FA2[8-7T6 MTM;Y;%M4T25,Z;J2/<"1)%>=)1+/Y;IY;1K"T:\A[+L+KUO?K-K=O::%H=SH MRZ1X`EU&^FNWM=2THM<3F6\TRP73)(KB6*-3.";NV;6Y2Y@A/Q#\79?3DALYE:78&.)&B!*1C=SD#V[ M`ON-3PO"=.\2Z=;W-IHVI6UW)XMD\/>)]*DFLM3C2?4'O=1T?7]+E4O,Z.&3 M[6LTD;26B;XHI'7?!7X$OB[2=,U+P-?/J6EV&HO9^++XVHO+6WN6MS-\07MY M?L[3PL8"\'[LF,+E&*Y(ZM+HM"9:+;8Q=6TO2;"]\4?V?8V%A>:7XM^'2Z"E MI:6]M):S21Z)$\%BL$:F.)[2YOU:)`%*239&W.!KEV$G;I:Q[^C#`VXQ@$$' MC_/O2V*7W#J!A0`4`!'&/PH`H_V;9"X:[%K;?:C()C<>1&)C*++ M5C$#G.P[>E`K=C$F\$>$)[ZSU*?PSH,VH:<\\EC>3:18R7-I)=7,U[62RFNM-MII+5Y[MK^9H'="8]] MZ[SG:1\[ENI-%^@)6^1IVGAW0[#4;W5[+2=-M-4U#_C_`-0M[*W@O+OE3^_N M(T#ODJI;)^8JI.2,TA[>5C/C\#^$H;^_U2+P]I$>HZHQ?4;Q;*$7%XQN8[PF MXDQF0FZABER?XD4]J-MM/^"!8;PGX<;6QXD;1=,/B`0"V_MAK.$W_D*AC6,7 M!7>JB-F48(^5B.AQ3\MK"M\K&S:6EO86\-I:11V]M;QK%!!$@CCAC485$5>% F4#M2_`$K%F@84`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!__]D_ ` end